Mirogabalin

Mirogabalin (brand name Tarlige; developmental code name DS-5565) is a medication developed by Daiichi Sankyo, a gabapentinoid. Gabapentin and pregabalin are also members of this class. As a gabapentinoid, mirogabalin binds to the α2δ subunit of voltage-gated calcium channel (1 and 2), but with significantly higher potency than pregabalin. It has shown promising results in Phase II clinical trials for the treatment of diabetic peripheral neuropathic pain.[1][2]

Mirogabalin
Clinical data
Trade namesTarlige
Other namesDS-5565
Routes of
administration
By mouth
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC12H19NO2
Molar mass209.289 g·mol−1
3D model (JSmol)

Phase III trial results:

In Japan, the company submitted a marketing application for treatment of peripheral neuropathic pain.[5] The medication was approved for neuropathic pain and postherpetic neuralgia in Japan in January 2019.[6]

References

  • "Mirogabalin". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.